Projected Price to Earnings: Inari (NARI)
Inari Medical, Inc. (NARI) dominates the non-injection thrombus removal segment thanks to unique patents. The business's forward P/E helps assess the stock's resilience to risks, while the 1143.70 level captures the current state. Stable revenue growth offsets R&D and legal expenses. Production scaling is driven by the automation of complex catheter assembly, which reduces reliance on human error.
Metric breakdowns and analytics for Inari Medical Corp (NARI)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Capital Inari Medical, Inc.|NARI - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Inari Medical, Inc.|NARI - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Inari Medical Inc|NARI - Company Long-Term Liabilities|Company Short-Term Debts Inari Medical|Quick Ratio inarimedical.com
- financial results and valuation multiples details:
NARI - Company Profit|Projected Future Earnings Inari Medical, Inc.|NARI - Business Payback Period|Forward P/E Multiple Inari|NARI - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Inari Medical Inc|NARI - Operating profit EBITDA|Earnings per share for the last twelve months Inari Medical|NARI - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months inarimedical.com|NARI - Earnings per share increase in current year|Earnings growth forecast for next year Inari Medical, Inc.
- company sales and revenue statistics:
Fundamental valuation:NARI Inari Medical
The integration of Inari Medical, Inc. (NARI) thrombectomy systems into surgical protocols is driving stable demand for high-margin consumables. The ratio of market value to projected earnings allows for an assessment of this premium, while changes in the company's forward P/E ratio help investors determine whether current quotes are justified by expected net income growth or if the asset is overvalued.
Competitors of Inari Medical, Inc.
Forward P/E Multiple DXCM|PEN - Projected Price to Earnings Ratio|Novanta Corp - Projected Price to Earnings|Forward P/E Multiple Haemonetics Company HAE|INSP: Projected Price to Earnings|procept-biorobotics.com - Market Cap to Future Earnings Ratio|CNMD: Forward P/E Multiple|PLSE - Market Cap to Projected Earnings|INMD (InMode Corp) - Forward P/E Multiple|Projected Price to Earnings Picard Group (PMI)|Projected Price to Earnings SRDX (Surmodics, Inc.)|SENS (Senseonics Holdings, Inc.) - Future Price to Earnings Multiple|Future Price to Earnings NeuroPace NPCE|TCMD - Projected Price to Earnings|SANUWAVE Health, Inc. - Forward P/E Multiple|Projected Price to Earnings Ratio Outset Medical Corp|ELMD: Forward P/E Multiple|Price to Future Earnings Ratio LNSR|RCEL (AVITA Medical) - Forward P/E Multiple|Profound Medical Corporation (PROF) - Market Cap to Projected Earnings|Forward P/E Multiple BDMD|Projected Price to Earnings edap-tms.com EDAP|Forward P/E Multiple APYX (Apyx Medical Corporation)|Forward P/E Multiple IceCure Medical Ltd. ICCM|LUNG - Future Price to Earnings|TELA: Future Price to Earnings|CTSO (cytosorbents.com) - Projected Price to Earnings|Sensus - Future Price to Earnings Multiple|ZYXI (Zynex, Inc.) - Forward P/E Multiple|Projected Price to Earnings Ratio electroCore Medical ECOR|Future Price to Earnings Vicarious Surgical Inc. (RBOT)|inspira-technologies.com (IINN) - Forward Price to Earnings Multiple|SeaStar Medical Holding Corp - Projected Price to Earnings|Forward P/E Multiple IRIDEX Corp IRIX|Intelligent Bio - Forward P/E Multiple|Market Cap to Projected Earnings Beyond Air, Inc. XAIR|Profusa (PFSA) - Future Price to Earnings|Price to Expected Earnings Ratio SSKN (STRATA Skin Sciences, Inc.)|Future Price to Earnings GlucoTrack|Projected Price to Earnings NanoVibronix Inc. (NAOV)|Forward P/E Multiple VERO|NUWE - Projected Price to Earnings Ratio|Future Price to Earnings Aethlon Medical, Inc. AEMD|ASXC: Price to Future Earnings Ratio|AVGR: Projected Price to Earnings|BioSig Technologies - Market Cap to Future Earnings Ratio|CUTR: Forward P/E Multiple|KNW - Market Cap to Projected Earnings|Future Price to Earnings Nevro|Price to Future Earnings Ratio RSLS (ReShape Lifesciences Inc)|Forward P/E Multiple SILK
